---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Humanistic burden and health-related quality of life. Topics: Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG, Health-state utilities elicited for BCG-unresponsive NMIBC and progression to cystectomy, Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ, Patient preferences for bladder-sparing treatment versus radical cystectomy, and 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG

> “Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months.”
> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health.”
> “At 12 months, the primary outcome of EORTC QLQ-C30 physical function did not differ between the BST arm and the RC arm (mean 85.4 [SD, 17.7] v 86.2 [17.6], respectively; ATE, 0.9 [95% CI, –0.6 to 2.4]; P = .22; Fig 2, Data Supplement, Table S10).”
> “Emotional function, cognitive function, global health, anxiety, and depression were significantly better in the RC arm 12 months after enrollment (Fig 2). There were no significant differences between treatment arms in role function and social function.”
> “Participants in the RC arm had significantly worse 12-month bowel and sexual summary scores than those in the BST arm.”
> “EORTC QLQ-C30 physical and role function were significantly worse in the RC arm at 3 months compared with the BST arm, but no significant treatment effects were observed by 9 months, including for physical function among participants age 75 years and older. Emotional function and anxiety were better in the RC arm at all follow-up time points. Urinary and bowel health were significantly worse in the RC arm at 3 months. By 12 months, there were no significant differences between the two treatments with respect to urinary health, but bowel health remained worse in the RC arm.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.8.1-2"></a>

### Health-state utilities elicited for BCG-unresponsive NMIBC and progression to cystectomy

> “The purpose of this study was to elicit the general public’s perspective on quality of life, measured as utility scores associated with treatment for Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC and disease progression, for supporting economic evaluation of newly developed treatments for NMIBC.”
> “Time trade-off (TTO) interviews were conducted with members of the UK general public.”
> “In total, 202 members of the general public participated.”
> “Mean utilities were 0.781 for No High-Grade Recurrence, 0.586 for High-Grade Recurrence, 0.572 for > 1-Year Post-cystectomy and 0.283 for metastatic disease. The First Year Post-cystectomy path health state had a mean utility of 0.288. Pairwise comparisons found statistically significant differences between utilities (p < 0.001), except between High-Grade Recurrence and > 1-Year Post-cystectomy (p = 0.524).”

Source: [Cooper et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9897878/)

<a id="topic-2.2.1.8.1-3"></a>

### Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ

> “We derived quality-adjusted life years (QALYs) from literature-reported utility values for bladder cancer health states (Table 3), adjusting for the health state's utility toll and duration.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

| Health state | Utility value | Range | Toll |
| --- | --- | --- | --- |
| Bladder cancer | “0.95” | “0.93–0.97” | “Lifetime” |
| Radical cystectomy with ileal conduit | “0.8” | “0.7–0.9” | “3 months” |
| Neoadjuvant chemotherapy, radical cystectomy, and ileal conduit | “0.694” | “0.6–0.9” | “3 months” |
| Post-cystectomy state | “0.9” | “0.8–0.95” | “Lifetime” |
| Metastatic disease | “0.62” | “0.5–0.7” | “Lifetime” |
| Recurrence | “0.8” | “0.75–0.95” | “3 months” |
| Disutility: acute minor toxicity (urinary tract infection) | “−0.15” | “0–0.3” | “2 weeks” |
| Disutility: acute major toxicity (hospitalization) | “−0.2” | “0–0.3” | “1 month” |
| Disutility: recurrence (TURBT, restaging) | “−0.15” | “0–0.3” | “1 month” |
| Disutility: radical cystectomy, major complications | “−0.07” | “0–0.1” | “1 month” |
| Disutility: radical cystectomy, minor complications | “−0.03” | “0–0.1” | “1 month” |
| Disutility: metastasis, initial | “−0.28” | “0.1–0.4” | “1.5 month” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-2.2.1.8.1-4"></a>

### Patient preferences for bladder-sparing treatment versus radical cystectomy

> “Patients with self-reported NMIBC completed an online discrete-choice experiment survey evaluating their preferences for efficacy-, safety-, and administration-related treatment attributes.”
> “A total of 206 respondents completed the survey. Reduced risks of progression to MIBC and NMIBC recurrence were the most important of the attributes evaluated, followed by, in order, chance of immune-related side effects requiring steroids, mode and frequency of administration, treatment-related fatigue, and urinary symptoms or infection. In fixed direct-elicitation questions, most patients (>70%) preferred bladder-sparing treatments over RC except when comparing repeated Bacillus Calmette-Guérin treatment to RC.”
> “Over 25% of respondents disagreed with the statement "My doctor asked me which treatment option I prefer" when reflecting on their shared decision-making experiences.”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41687978/)

<a id="topic-2.2.1.8.1-5"></a>

### Treatment burden of intravesical therapy: travel, caregiver support, and daily activities

> “Two hundred thirty-three patients responded to the survey with median age of 70 years (range 33-88 years). Two-thirds of respondents (66%, 151/232) had received greater than 12 bladder instillations.”
> “Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. Among those surveyed, 72% (168/232) reported openness to receiving in-home intravesical instillations and 54% (122/228) answered that in-home instillations would make the treatment process less disruptive to their lives.”

Source: [Myers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993341/)

<a id="topic-2.2.1.8.1-6"></a>

### Quality of life with frequent intravesical instillations: systematic review

> “A total of 17 studies were selected, comprising 6 qualitative, 8 quantitative, and 3 mixed-methods designs, totaling 20,045 patients. Frequent instillations were associated with increased urinary symptoms (e.g., urgency and dysuria), fatigue, and emotional distress. Withdrawal rates were high (up to 90%) in intensive schedules, particularly during the first year, due to treatment burden and side effects.”
> “Frequent intravesical instillations can significantly impair QoL, particularly among older patients.”

Source: [Griebsch et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647504/)

<a id="topic-2.2.1.8.1-7"></a>

### Quality of life during cystoscopic surveillance: systematic review

> “NMIBC survivors had significantly lower QoL compared to the general population, Surveillance strategies involving repeated intravesical therapies and cystoscopies have a negative impact on QoL with impaired physical function and mental health.”
> “Surveillance is also tailored according to the risk strata. The frequency of surveillance increases with the increase in risk accordingly impacting the QoL”
> “most guidelines advocate 3-month cystoscopy for 2 years, then every 6 months for 5 years and then annually (39), provided there is no recurrence.”

Source: [Nayak et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261437/)

<a id="topic-2.2.1.8.1-8"></a>

### Quality of life of NMIBC survivors compared with the general population

> “Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function.”

Source: [Jung et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29863576/)

<a id="topic-2.2.1.8.1-9"></a>

### Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: N-803 plus BCG

> “Both cohort A patients with carcinoma in situ with or without Ta/T1 disease and cohort B patients with high-grade Ta/T1 papillary disease who received N-803 plus BCG therapy completed the EORTC (European Organization for Research and Treatment of Cancer) Core 30 and Quality of Life NMIBC-Specific 24 questionnaires at baseline and months 6, 12, 18, and 24 on study.”
> “On study, mean physical function (PF) and global health (GH) scores remained relatively stable from baseline for cohorts A (n = 86) and B (n = 78).”
> “NMIBC-Specific 24 summary scores also remained stable on study for both cohorts.”

Source: [Chamie et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38226931/)

<a id="topic-2.2.1.8.1-10"></a>

### Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: gemcitabine and docetaxel

> “PRO assessments were performed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and NMIBC24 questionnaires.”
> “Sixty-three patients were included.”
> “Urinary symptom burden, global function, and functional outcomes remained stable during treatment.”

Source: [Tan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42869744/)

Additional sources: [Mohamed et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33423864/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
